Olema Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Palazestrant is advancing in pivotal trials for ER+/HER2- breast cancer, showing strong efficacy in both ESR1 mutant and wild type populations, with key readouts expected in fall and 2028. OP-3136, a selective KAT6 inhibitor, aims for improved tolerability and will present initial data in Q2.
-
Recent data validate the efficacy of SERD/CERAN therapies in ER-positive, HER2-negative breast cancer, with palazestrant showing strong combinability and exposure. Ongoing trials and a robust pipeline, including a KAT6 inhibitor, position the company for significant market impact.
-
The summit highlighted the differentiation of palazestrant as a complete estrogen receptor antagonist with strong PK and tolerability, targeting both ESR1 wild-type and mutant breast cancer. Key trials OPERA-01 and OPERA-02 are progressing, with pivotal data expected in fall 2024 and late-decade, respectively.
-
The company is advancing palazestrant in two phase 3 trials for ER-positive, HER2-negative breast cancer, with a U.S. launch planned and significant market potential. Strong clinical data, strategic partnerships, and a new commercial focus position it for growth.
-
The conference highlighted a robust clinical pipeline targeting ER-positive, HER2-negative breast cancer, with key phase III readouts for palazestrant expected this year and a strong focus on differentiation through efficacy and combination strategies. Commercialization plans include a U.S. launch in 2027 and global partnerships.
Fiscal Year 2025
-
Palazestrant is advancing in two phase III trials, targeting both ESR1-mutant and wild-type breast cancer populations, with key data readouts expected next year. Recent positive industry results have renewed confidence in SERDs, and ongoing combination studies may further expand market potential.
-
The discussion highlighted progress on pivotal trials for a complete estrogen receptor antagonist in breast cancer, with key readouts expected in 2026 and 2028. Recent positive competitor data and strong internal results in both ESR1 mutant and wild type populations support confidence in market potential and future growth.
-
Significant progress was highlighted for two clinical programs targeting ER-positive, HER2-negative breast cancer, with palazestrant showing superior efficacy and safety in phase III trials and OP-3136 advancing in early-phase studies. Key pivotal readouts and potential product launches are expected between 2025 and 2027.
-
Palazestrant demonstrates strong efficacy in both ESR1 mutant and wild-type breast cancer, with pivotal trials OPERA-01 and OPERA-02 progressing and significant market potential if wild-type activity is confirmed. Strategic collaborations and a robust financial position support ongoing development.
-
Palazestrant is advancing in two Phase 3 trials for metastatic breast cancer, showing strong efficacy in both ESR1-mutant and wild-type patients. Combination strategies with CDK4/6 inhibitors are progressing, with no significant safety issues and promising PFS data. The CDK4 inhibitor program is expanding into new indications, with key data expected in 2025.
-
Management highlighted robust progress in breast cancer programs, with palazestrant advancing in pivotal trials and showing strong efficacy in both mutant and wild-type settings. Strategic collaborations and upcoming data readouts at ESMO and in 2025–2026 are expected to drive further differentiation.
-
Palisestrant is advancing in phase 3 trials for ER+ HER2- breast cancer, targeting both ESR1 mutant and wild type populations, with key data readouts expected next year. Strategic collaborations and a robust pipeline, including a Cat6 inhibitor, position the company for significant market expansion.
-
Focused on ER-positive, HER2-negative breast cancer, the pipeline features palazestrant in phase III and OP-3136 in phase I, targeting large market opportunities. Key upcoming milestones include pivotal trial readouts and new data presentations, with differentiation in both mutant and wild type populations.
-
Key updates include progress on two phase III trials for palazestrant in breast cancer, a new Pfizer collaboration for a first-in-human combo study, and a Novartis partnership offsetting major trial costs. Upcoming ESMO data will provide more mature efficacy results and further differentiation for palazestrant.
-
Major clinical data from phase II and III trials are expected within the next 12–18 months, with palazestrant positioned as a best-in-class therapy due to its efficacy in both ESR1 mutant and wild type populations and strong combination potential. Strategic partnerships and robust funding support imminent trial initiations and future growth.
-
Palazestrant is advancing through phase III trials, showing strong efficacy in both ESR1 mutant and wild-type breast cancer, with combination studies and a new CDK4/6 inhibitor also progressing. Upcoming competitor readouts and ongoing enrollment updates are expected to shape the evolving SERD landscape.
-
OPERA-01 is on track for 2026 data, with dose selection and expanded enrollment underway. Palazestrant's CERAN profile may offer key differentiation, and the KAT6 inhibitor program is advancing with promising preclinical synergy. Market potential and pipeline breadth remain strong.
-
Palazestrant is advancing in phase 3 trials for ER-positive, HER2-negative breast cancer, with promising PFS data and a new first-line trial launching soon. The pipeline includes a differentiated KAT6 inhibitor, OP-3136, with expansion into multiple cancer types planned.
-
Palazestrant is advancing through late-stage trials, showing best-in-class efficacy in ER-positive, HER2-negative breast cancer, with strong potential in both mutant and wild-type populations. The KAT6 inhibitor OP-3136 is progressing in phase one, and robust financial resources support ongoing and future programs.
-
Palazestrant is advancing through two pivotal phase III trials, with strong early data in both ESR1 mutant and wild type breast cancer, and a unique collaboration with Novartis for frontline studies. The KAT6 program is also progressing, with combination strategies and multiple catalysts expected in 2025.
-
Palazestrant is advancing through pivotal phase III trials, showing strong efficacy and tolerability in both ESR1 mutant and wild-type breast cancer. Backed by robust financials and a Novartis partnership, the pipeline is expanding, with commercial launch targeted for 2027.
Fiscal Year 2024
-
Updated phase Ib/II data show palazestrant plus ribociclib delivers strong efficacy and safety in advanced ER+/HER2- breast cancer, outperforming benchmarks and supporting advancement to pivotal phase III trials. Strategic partnerships and funding position the pipeline for continued progress.
-
Panelists highlighted major clinical advances in breast and biliary tract cancer, with Olema and Zymeworks advancing novel targeted therapies and combination strategies. Coherus' Loqtorzi gained preferred status for NPC, and recent deals are fueling pipeline expansion and innovation.
-
Palazestrant is advancing as a differentiated CERAN/SERD with strong monotherapy and combination data, supported by a major Novartis partnership and robust funding. Key milestones include a 1,000-patient phase III trial, KAT6 clinical entry, and ongoing expansion of combination strategies.
-
Palazestrant, a complete oral SERD, is advancing in both monotherapy and combination with ribociclib, with new efficacy and safety data to be presented at San Antonio. The company is exploring partnerships to fund a pivotal first-line trial, targeting a multi-billion dollar market.
-
The discussion highlighted the evolving breast cancer treatment landscape, emphasizing the need for new therapies post-CDK4/6 progression. Palazestrant and KAT6 inhibitor OP-3136 are advancing in clinical trials, with key data readouts and regulatory milestones expected through 2026.